Tag: treatment

CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company’s aprevo^® personalized interbody implants.

HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025.

BOCA RATON, FL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has signed a Letter of Intent (LOI) to explore a strategic collaboration with Solrise Group Ltd, creators of Solflare, the leading Solana-native wallet serving over 4 million active users.

Vast majority of patients dosed completed the full 12-week study

All amounts in U.S. dollars unless otherwise indicated

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”).

New York, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Franklin Morgan & Associates is proud to announce that in a recent ruling, the Dubai International Arbitration Centre (DIAC) has awarded the firm $113 million in a cross-border commercial dispute. The case created a big stir in the legal community not only because of the scope of the dispute, but also for how it positioned Dubai to the world as a high-value destination for international arbitration.